Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
19/08/2026 01:59
BRIEF-Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors Aug 19 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:
INTENDS TO ENTER NEGOTIATIONS WITH ITS CREDITORS
FY26 FINANCIAL REPORT EXPECTED TO INCLUDE A MATERIAL UNCERTAINTY IN RELATION TO GOING CONCERN
MAJOR COST REDUCTIONS IMPLEMENTED, EXPECTED TO REDUCE ANNUALISED EXPENDITURE BY AROUND A$4 MILLION
CONDUCTED PROCESS TO EXPLORE POTENTIAL TO SELL, OUT LICENCE OR PARTNER CHM CDH17 ASSET AND PROGRAMME
INTENDS TO RE-ENGAGE WITH POTENTIAL PARTNERS AS IN VIVO PATHWAY ADVANCES
INTENDS TO ENTER NEGOTIATIONS WITH CREDITORS, INCLUDING PROVIDER OF CONVERTIBLE FACILITY, TO REDUCE LIABILITIES
Further company coverage: CHM.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial